ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

INO Inovio Pharmaceuticals Inc New

11.03
0.03 (0.27%)
10 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Inovio Pharmaceuticals Inc New NASDAQ:INO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.03 0.27% 11.03 11.04 11.30 11.20 10.80 11.00 121,915 00:57:10

INOVIO to Present at the H.C. Wainwright 25th Annual Global Investment Conference

29/08/2023 1:00pm

PR Newswire (US)


Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart


From May 2023 to May 2024

Click Here for more Inovio Pharmaceuticals Charts.

PLYMOUTH MEETING, Pa., Aug. 29, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO will present at the H.C. Wainwright 25th Annual Global Investment Conference.

H.C. Wainwright 25th Annual Global Investment Conference
Date: Tuesday, September 12, 2023
Time: 4:30 PM ET
Format: Company Presentation

During the conference, Dr. Shea and members of INOVIO's management team will conduct one-on-one meetings with registered investors.

A webcast of the presentation will be available on the INOVIO Investor Relations Events page at https://ir.inovio.com/events-and-presentations/default.aspx. A replay of the webcast will be available for 90 days after the date of the presentation.

About INOVIO

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's DNA medicines in development are delivered using its investigational proprietary device, CELLECTRA®, to produce immune responses against targeted pathogens and cancers. For more information, visit www.inovio.com.

Contacts

Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267) 440-4298 thomas.hong@inovio.com

Cision View original content:https://www.prnewswire.com/news-releases/inovio-to-present-at-the-hc-wainwright-25th-annual-global-investment-conference-301911827.html

SOURCE INOVIO Pharmaceuticals, Inc.

Copyright 2023 PR Newswire

1 Year Inovio Pharmaceuticals Chart

1 Year Inovio Pharmaceuticals Chart

1 Month Inovio Pharmaceuticals Chart

1 Month Inovio Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock